Intellia Therapeutics, Inc. (NTLA): Entry into a Material Definitive Agreement

Intellia Therapeutics (NTLA) secured a $400 million debt facility from OrbiMed, with $75 million funded at closing and $225 million tied to milestones for lonvo-z, a CRISPR gene-editing therapy. The facility provides financial flexibility for lonvo-z's development and potential U.S. launch for hereditary angioedema (HAE). NTLA shares are up 0.63% at $12.76.

Ark Invest's Cathie Wood added to existing holdings, including Nvidia (NVDA), Broadcom (AVGO), and Intellia Therapeutics (NTLA). Nvidia reported strong Q2 results with $96.2B revenue and raised guidance. Broadcom expects 85% revenue growth. Intellia Therapeutics received a Buy rating with a $24 price target. Ark's Genomic Revolution ETF (ARKG) gained 64% YTD.

Intellia Therapeutics (NTLA) stock rose 5% premarket after positive Phase 3 data for its CRISPR-based therapy, Lonvo-z, showed significant reductions in hereditary angioedema (HAE) attacks. The company reported 89% and 91% reductions in attacks requiring rescue medication and moderate-to-severe attacks, respectively, compared to placebo. Intellia aims for FDA approval and U.S. launch in early 2027.

A phase 3 trial showed that a single dose of lonvoguran ziclumeran (lonvo-z or NTLA-2002) reduced hereditary angioedema attacks by 87% compared to placebo. 62% of treated patients remained attack-free. Adverse events were mostly mild, with no serious events reported. The study was funded by Intellia Therapeutics.

Intellia (NTLA) discussed Q2 2026 updates for lonvo-z in hereditary angioedema, citing a New England Journal manuscript showing a 23-point improvement in quality-of-life score and attack-rate reductions in the lonvo-z arm, with all patients remaining free of long-term prophylaxis as of the data cutoff. The company expects FDA BLA acceptance for lonvo-z by year-end and plans a U.S. launch in H1 next year. It also resumed Q3 Phase III enrollment for nex-z after resolving clinical holds.

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 EPS of -$0.80, in line with consensus, but collaboration revenue fell to $7.7 million versus an estimated ~$13.0 million. Net loss was $106.6 million. The company said Phase 3 HAELO data for lonvo-z reduced attacks by 87% and expects lonvo-z BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4 million.